Literature DB >> 9248746

Relevance of clinical and laboratory findings in the diagnosis of cytomegalovirus encephalitis in patients with AIDS.

C Mussini1, N Mongiardo, G Manicardi, F Trenti, A Alessandrì, F Paolillo, A Catania, M Portolani, M Pecorari, V Borghi, G Ficarra, A Cossarizza, B De Rienzo.   

Abstract

A retrospective evaluation was conducted in patients with AIDS and an autopsy diagnosis of cytomegalovirus (CMV) encephalitis to determine the relevance of clinical and laboratory findings in establishing a diagnosis. On autopsy of 100 patients, CMV encephalitis was diagnosed in 13 patients; eight had periventricular CMV encephalitis, four micronodular CMV encephalitis, and one both conditions. Seven patients had had a CMV infection previously (6 cases of retinitis, 1 case of colitis), and at the onset of encephalitis all of them were receiving a maintenance dose of ganciclovir. Examination of the CSF showed specific changes in patients with periventricular encephalitis. CT revealed no characteristic findings, while MRI showed an increased signal intensity on T2 weighted images. CMV DNA amplification by nested PCR was performed in nine patients with CMV encephalitis; PCR was positive in eight patients whose CSF was collected during CMV encephalitis, and negative in one patient whose CSF was collected six months before death. In conclusion, some clinical findings suggest a presumptive diagnosis, especially of periventricular encephalitis, and nested PCR appears to be a reliable and rapid technique for making an antemortem diagnosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9248746     DOI: 10.1007/bf02471907

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  44 in total

1.  Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS.

Authors:  R Enting; J de Gans; P Reiss; C Jansen; P Portegies
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

2.  Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Authors:  W L Drew; R C Miner; D F Busch; S E Follansbee; J Gullett; S G Mehalko; S M Gordon; W F Owen; T R Matthews; W C Buhles
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

3.  Human pharmacokinetics of the antiviral drug DHPG.

Authors:  C Fletcher; R Sawchuk; B Chinnock; P de Miranda; H H Balfour
Journal:  Clin Pharmacol Ther       Date:  1986-09       Impact factor: 6.875

4.  Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.

Authors:  J F Manischewitz; G V Quinnan; H C Lane; A E Wittek
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

5.  Ganciclovir treatment of cytomegalovirus ventriculitis in a patient infected with human immunodeficiency virus.

Authors:  T A Price; R A Digioia; G L Simon
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

6.  Penetration of foscarnet into cerebrospinal fluid of AIDS patients.

Authors:  F Raffi; A M Taburet; B Ghaleh; A Huart; E Singlas
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis.

Authors:  U R Hengge; N H Brockmeyer; R Malessa; U Ravens; M Goos
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

8.  Ganciclovir therapy for cytomegalovirus (CMV) infection of the central nervous system in AIDS patients: monitoring by CMV DNA detection in cerebrospinal fluid.

Authors:  P Cinque; F Baldanti; L Vago; M R Terreni; F Lillo; M Furione; A Castagna; A D Monforte; A Lazzarin; A Linde
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

9.  Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS.

Authors:  D Salmon; F Lacassin; M Harzic; C Leport; C Perronne; F Bricaire; F Brun-Vezinet; J L Vilde
Journal:  J Med Virol       Date:  1990-11       Impact factor: 2.327

10.  Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

Authors:  J Sjövall; S Bergdahl; G Movin; S Ogenstad; M Saarimäki
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.